News / Taiwan / economic_daily
Ever Supreme Bio Tech Reports Strong August Revenue Growth as CAR001 Clinical Trials Advance
Health Technology · Biotechnology · economic_daily · 2026-09-01
6712
Ever Supreme Bio Tech announced an 11% monthly revenue increase for August, driven by steady demand for cell therapy services and CDMO operations while advancing its CAR001 cancer treatment.
What Happened
Revenue Performance: Ever Supreme Bio Tech reported August revenue of NT$109 million, marking a 21% year-over-year increase and an 11% month-over-month rise. Cumulative revenue for the first eight months of the year reached NT$669 million, reflecting a 17% growth compared to the same period last year.
Growth Drivers: The company attributed its strong financial results to the steady expansion of its cell storage, cell preparation services, and CDMO business. These core segments provide a stable financial foundation that supports the company's ongoing research and development initiatives.
Clinical Progress: The company's flagship CAR001 therapy has successfully completed Phase I trials and is currently in the Phase IIa stage of clinical development. This treatment utilizes AI-assisted design and mRNA non-viral electroporation technology to target advanced or refractory solid tumors.
Future Outlook: Looking ahead, Ever Supreme intends to leverage its CDMO and cell therapy services as a stable operational base while advancing its pipeline, including EXO001 and dEV001. The company remains focused on deepening its expertise in AI, mRNA, and exosome technologies to facilitate future international licensing and clinical expansion.